今世緣(603369.SH):子公司酉緣投資收回東證睿芾全部實繳出資1億元及取得投資收益1348.36萬元
格隆匯 12 月 18日丨今世緣(603369.SH)公佈,公司全資子公司上海酉緣投資管理有限責任公司(“酉緣投資”)於2019年4月以自有資金出資1億元入夥諸暨東證睿芾投資合夥企業(有限合夥)(“東證睿芾”或“基金”)。
近日,因東證睿芾實際投資的項目已經達到退出標準,經全體合夥人協商一致並經普通合夥人同意,酉緣投資收回全部投資份額後退出東證睿芾。根據東證睿芾收益分配規則,此次退出時,酉緣投資收回了全部實繳出資金額1億元,取得投資收益1348.36萬元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.